Objective This study was designed to evaluate the efficacy and safety of using dalteparin instead of UFH in selective percutaneous coronary intervention (PCI) of patients with coronary heart disease (CHD).
第一作者机构:[1]Capital Univ Med Sci, Dept Cardiol, Tongren Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Shi Xu-bo,Li Tian-chang,Wang Hong-yu,et al.THE SAFETY AND EFFICIENCY OF DALTEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION[J].HEART.2010,96:A168-A169.doi:10.1136/hrt.2010.208967.544.
APA:
Shi Xu-bo,Li Tian-chang,Wang Hong-yu,Sun Gen-yi,Chen Bu-xing&Wang Ming-sheng.(2010).THE SAFETY AND EFFICIENCY OF DALTEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION.HEART,96,
MLA:
Shi Xu-bo,et al."THE SAFETY AND EFFICIENCY OF DALTEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION".HEART 96.(2010):A168-A169